# Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

> **NCT01734057** · PHASE3 · WITHDRAWN · sponsor: **Shandong University**

## Conditions studied

- Purpura
- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** recombinant human thrombopoietin (rhTPO); rituximab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01734057
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-07
- **Primary completion:** 2013-07
- **Final completion:** 2013-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No eligible patient was enrolled.
- **Last updated:** 2016-04-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01734057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01734057, "Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01734057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*